Etoposide in leukemia, lymphoma and bone marrow transplantation
Open Access
- 31 December 1989
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 13 (8) , 639-650
- https://doi.org/10.1016/0145-2126(89)90052-0
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Busulphan versus combination chemotherapy for initial treatment of chronic granulocytic leukaemiaAmerican Journal of Hematology, 1986
- Ifosfamide and etoposide as salvage therapy for non‐Hodgkin's lymphomaScandinavian Journal of Haematology, 1986
- Phase I study of VP‐16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemiaMedical and Pediatric Oncology, 1985
- Acute myelogenous leukemia: Successful treatment of relapse with cytosine arabinoside, VP 16ndash;213, vincristine and vinblastine (A-triple-V)European Journal of Cancer and Clinical Oncology, 1982
- Cis-dichlorodiammineplatinum (II) (cis-platinum) and etoposide for patients with refractory lymphomasCancer Treatment Reviews, 1982
- VP 16–213 and cyclophosphamide in the treatment of refractory acute nonlymphocytic leukemia with monocytic featuresMedical and Pediatric Oncology, 1981
- Rapid remission induction in adult acute non-lymphoblastic leukaemiaPublished by Elsevier ,1978
- Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213Published by Elsevier ,1975
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsPublished by Elsevier ,1973